Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Qualitative and quantitative changes in coronary plaque associated with atorvastatin therapy.

Hirayama A, Saito S, Ueda Y, Takayama T, Honye J, Komatsu S, Yamaguchi O, Li Y, Yajima J, Nanto S, Takazawa K, Kodama K.

Circ J. 2009 Apr;73(4):718-25. Epub 2009 Feb 18.

2.

Plaque stabilization by intensive LDL-cholesterol lowering therapy with atorvastatin is delayed in type 2 diabetic patients with coronary artery disease-Serial angioscopic and intravascular ultrasound analysis.

Takayama T, Hiro T, Ueda Y, Honye J, Komatsu S, Yamaguchi O, Li Y, Yajima J, Takazawa K, Nanto S, Saito S, Hirayama A, Kodama K.

J Cardiol. 2013 Jun;61(6):381-6. doi: 10.1016/j.jjcc.2013.01.010. Epub 2013 Mar 9.

3.

Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy.

Takano M, Mizuno K, Yokoyama S, Seimiya K, Ishibashi F, Okamatsu K, Uemura R.

J Am Coll Cardiol. 2003 Aug 20;42(4):680-6.

4.

Statin-induced structural changes in coronary plaques evaluated by intracoronary imaging.

Komiyama N.

Circ J. 2009 Apr;73(4):628-9. No abstract available.

5.

Assessment of plaque vulnerability by angioscopic classification of plaque color.

Ueda Y, Ohtani T, Shimizu M, Hirayama A, Kodama K.

Am Heart J. 2004 Aug;148(2):333-5.

PMID:
15309005
6.

Plaque-stabilizing effect of atorvastatin is stronger for plaques evaluated as more unstable by angioscopy and intravenous ultrasound.

Hirayama A, Saito S, Ueda Y, Takayama T, Honye J, Komatsu S, Yamaguchi O, Li Y, Yajima J, Nanto S, Takazawa K, Kodama K.

Circ J. 2011;75(6):1448-54. Epub 2011 Apr 19.

7.

Influence of achieved low-density lipoprotein cholesterol level with atorvastatin therapy on stabilization of coronary plaques: sub-analysis of the TWINS study.

Okada K, Ueda Y, Takayama T, Honye J, Komatsu S, Yamaguchi O, Li Y, Yajima J, Takazawa K, Nanto S, Saito S, Hirayama A, Kodama K.

Circ J. 2012;76(5):1197-202. Epub 2012 Feb 17.

8.

Multiple yellow plaques assessed by angioscopy with quantitative colorimetry in patients with myocardial infarction.

Inami S, Ishibashi F, Waxman S, Okamatsu K, Seimiya K, Takano M, Uemura R, Sano J, Mizuno K.

Circ J. 2008 Mar;72(3):399-403.

9.

Angioscopic evaluation of atherosclerotic plaques: validation by histomorphologic analysis and association with stable and unstable coronary syndromes.

Thieme T, Wernecke KD, Meyer R, Brandenstein E, Habedank D, Hinz A, Felix SB, Baumann G, Kleber FX.

J Am Coll Cardiol. 1996 Jul;28(1):1-6.

10.

In vivo comparison of optical coherence tomography and angioscopy for the evaluation of coronary plaque characteristics.

Takano M, Jang IK, Inami S, Yamamoto M, Murakami D, Okamatsu K, Seimiya K, Ohba T, Mizuno K.

Am J Cardiol. 2008 Feb 15;101(4):471-6. doi: 10.1016/j.amjcard.2007.09.106.

PMID:
18312760
11.

Number of yellow plaques detected in a coronary artery is associated with future risk of acute coronary syndrome: detection of vulnerable patients by angioscopy.

Ohtani T, Ueda Y, Mizote I, Oyabu J, Okada K, Hirayama A, Kodama K.

J Am Coll Cardiol. 2006 Jun 6;47(11):2194-200. Epub 2006 May 15.

12.

Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naive patients: the VENUS study.

Lee SW, Hau WK, Kong SL, Chan KK, Chan PH, Lam SC, Tam FC, Wong MK, Chan CW, Lam YM, Tse HF, Chan RH.

Circ J. 2012;76(11):2662-72. Epub 2012 Aug 2.

13.

Plaque color analysis by the conventional yellow-color grading system and quantitative measurement using LCH color space.

Okada K, Ueda Y, Oyabu J, Ogasawara N, Hirayama A, Kodama K.

J Interv Cardiol. 2007 Oct;20(5):324-34.

PMID:
17880328
14.

The healing process of infarct-related plaques. Insights from 18 months of serial angioscopic follow-up.

Ueda Y, Asakura M, Yamaguchi O, Hirayama A, Hori M, Kodama K.

J Am Coll Cardiol. 2001 Dec;38(7):1916-22.

15.

Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy.

Undas A, Brummel-Ziedins KE, Potaczek DP, Stobierska-Dzierzek B, Bryniarski L, Szczeklik A, Mann KG.

J Thromb Haemost. 2006 Nov;4(11):2397-404. Epub 2006 Aug 14.

16.

Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study.

Asakura M, Ueda Y, Yamaguchi O, Adachi T, Hirayama A, Hori M, Kodama K.

J Am Coll Cardiol. 2001 Apr;37(5):1284-8.

17.

Angioscopically-determined extent of coronary atherosclerosis is associated with severity of acute coronary syndrome.

Ueda Y, Oyabu J, Okada K, Murakawa T, Hirayama A, Kodama K.

J Invasive Cardiol. 2006 May;18(5):220-4.

PMID:
16670449
18.

Atheromatous plaque cap thickness can be determined by quantitative color analysis during angioscopy: implications for identifying the vulnerable plaque.

Miyamoto A, Prieto AR, Friedl SE, Lin FC, Muller JE, Nesto RW, Abela GS 2nd.

Clin Cardiol. 2004 Jan;27(1):9-15.

19.
20.

Relationship between neointimal coverage of sirolimus-eluting stents and lesion characteristics: a study with serial coronary angioscopy.

Yamamoto M, Okamatsu K, Inami S, Takano M, Yokoyama S, Ohba T, Ibuki C, Hata N, Seino Y, Mizuno K.

Am Heart J. 2009 Jul;158(1):99-104. doi: 10.1016/j.ahj.2009.04.016.

PMID:
19540398

Supplemental Content

Support Center